309 related articles for article (PubMed ID: 29642146)
1. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
Lv X; Zhang Y; Niu Y; Song Q; Zhao Q
Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
3. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
4. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.
Hao G; Wang Z; Guo R; Chen Z; Wang X; Zhang L; Li W
BMC Cardiovasc Disord; 2014 Oct; 14():148. PubMed ID: 25344747
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
[TBL] [Abstract][Full Text] [Related]
6. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
[TBL] [Abstract][Full Text] [Related]
10. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
[TBL] [Abstract][Full Text] [Related]
11. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Liu X; Ma L; Li Z
J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
[TBL] [Abstract][Full Text] [Related]
15. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
[TBL] [Abstract][Full Text] [Related]
17. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH; Hall AS
Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
[TBL] [Abstract][Full Text] [Related]
18. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
Xie Q; Tang S; Li Y
Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
Al Khalaf MM; Thalib L; Doi SA
Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
Avgerinos I; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2023 Oct; 25(10):3020-3029. PubMed ID: 37435776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
